RARE DISEASE
Autosomal dominant dopa-responsive dystonia
Autosomal dominant dopa-responsive dystonia
Autosomal dominant dopa-responsive dystonia
Synonyms: Autosomal dominant Segawa syndrome, DYT5a, GTPCH1-deficient DRD, GTPCH1-deficient dopa-responsive dystonia, HPD with marked diurnal fluctuation, Hereditary progressive dystonia with marked diurnal fluctuation
Synonyms: Autosomal dominant Segawa syndrome, DYT5a, GTPCH1-deficient DRD, GTPCH1-deficient dopa-responsive dystonia, HPD with marked diurnal fluctuation, Hereditary progressive dystonia with marked diurnal fluctuation
Synonyms: Autosomal dominant Segawa syndrome, DYT5a, GTPCH1-deficient DRD, GTPCH1-deficient dopa-responsive dystonia, HPD with marked diurnal fluctuation, Hereditary progressive dystonia with marked diurnal fluctuation
Drug discovery
0
drugs
With orphan designations
Overview
Autosomal dominant dopa-responsive dystonia (DRD), most commonly caused by GCH1 mutations, is a rare neurometabolic disorder characterized by childhood-onset dystonia (typically lower-limb), diurnal symptom fluctuations, and parkinsonism. It demonstrates dramatic, sustained response to low-dose levodopa without motor complications. Non-motor symptoms (sleep disturbances, depression) may occur [1][6][16].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases
Research Papers
76 drug discovery papers about Autosomal dominant dopa-responsive dystonia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
76 drug discovery papers about Autosomal dominant dopa-responsive dystonia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-05-31 | Segawa Syndrome (Dopa-Responsive Dystonia): Current Concepts in Pathogenesis, Clinical Spectrum, Diagnosis, and Contemporary Management
Segawa syndrome, also known as dopa-responsive dystonia (DRD), is a rare inherited neurometabolic movement disorder characterized by childhood-onset dystonia, gait abnormalities, marked diurnal fluctuation, and dramatic responsiveness to low-dose levodopa therapy. [1,2] Since its original description by Segawa and colleagues in 1976, substantial advances have occurred in the understanding of the molecular genetics, neurotransmitter biochemistry, clinical heterogeneity, and therapeutic responsiveness of this disorder. [1,3] Classical Segawa syndrome is most commonly associated with autosomal dominant mutations involving the guanosine triphosphate cyclohydrolase I (GCH1) gene, resulting in impaired tetrahydrobiopterin (BH4) synthesis and subsequent dopamine deficiency within the nigrostriatal pathway. [3,4] Additional pathogenic variants involving TH, SPR, and related neurotransmitter biosynthetic pathways have expanded the phenotypic spectrum to include atypical and complex forms associated with parkinsonism, developmental delay, autonomic dysfunction, psychiatric manifestations, and cognitive impairment. [5,11] The disorder frequently presents diagnostic challenges because of significant phenotypic overlap with cerebral palsy, hereditary spastic paraplegia, juvenile Parkinson disease, idiopathic dystonia, and neurodegenerative disorders. [6,10,21] Delayed diagnosis remains common despite the existence of highly effective treatment, resulting in avoidable disability, skeletal deformities, psychosocial impairment, and reduced quality of life. [18,21] The hallmark clinical feature remains a dramatic and sustained response to levodopa therapy, which distinguishes DRD from most progressive neurodegenerative movement disorders. [8] Recent advances in molecular diagnostics, next-generation sequencing, cerebrospinal fluid neurotransmitter analysis, and functional neuroimaging have improved disease recognition and expanded understanding of genotype–phenotype correlations. [5,10,11] Nevertheless, contemporary controversies persist regarding diagnostic classification, atypical phenotypes, long-term disease progression, neuropsychiatric involvement, and optimization of individualized therapeutic strategies. [17,22] This comprehensive descriptive review examines the epidemiology, molecular pathogenesis, neurochemical mechanisms, clinical presentation, diagnostic evaluation, differential diagnosis, treatment approaches, prognosis, contemporary controversies, limitations of current evidence, and future research directions related to Segawa syndrome.
2026-05-19 | A case of dopa-responsive dystonia with a novel GCH1 variant c.579 C > G (p.Ile193Met).
Dopa-responsive dystonia (DRD) is an underdiagnosed inherited movement disorder characterized by childhood-onset progressive dystonia, diurnal symptom luctuation, and exquisite responsiveness to low-dose levodopa. Misdiagnosis as epilepsy, cerebral palsy, or juvenile Parkinsonism is common due to overlapping phenotypes and non-specific auxiliary examinations. A 22-year-old Chinese female presented with an 18-year history of right-sided limb and perioral involuntary movements, slurred speech, and progressive hypertonia. She was misdiagnosed with epilepsy for over a decade with no response to antiepileptic therapy. Brain MRI, EEG, and routine laboratory tests were unremarkable. Whole-exome sequencing (WES) identiied a heterozygous guanosine triphosphate cyclohydrolase-1 (GCH1) variant c.579C>G (p.Ile193Met), classified as a variant of uncertain signiicance (VUS) per American College of Medical Genetics and Genomics (ACMG) guidelines. Low-dose levodopa/benserazide (Madopar 0.125 g tid) induced dramatic symptomatic improvement, with sustained remission at 6-month follow-up. This case expands the GCH1 mutational spectrum of DRD and highlights the critical role of levodopa trial in unexplained dystonia, even in the absence of diurnal luctuation. Early recognition and intervention are pivotal for favorable prognosis.
2026-04-12 | Genetic analysis reveals phenotypic variability in three Colombian families with dopa-responsive dystonia: novel genotype-phenotype correlations.
BACKGROUND: Dopa-responsive Dystonia (DRD) due to GTP cyclohydrolase 1 (GTPCH1) deficiency is a neurogenetic disorder caused by pathogenic GCH1 variants. Tetrahydrobiopterin (BH4) deficiency impairs dopamine synthesis in the basal ganglia, leading to childhood-onset dystonia with excellent response to levodopa. CASE PRESENTATION: We report eight patients from three unrelated families with GCH1 (NM_000161.3) variants: c.142 C > T; p.(Gln48*), c.241T > C; p.(Ser81Pro), and c.607G > A; p.(Gly203Arg). Two individuals homozygous for c.142 C > T showed phenotypic discordance. Mean age at onset was 7.3 years (range: 6–12), with an average diagnostic delay of 13.4 years. All symptomatic individuals responded well to low-dose levodopa. DISCUSSION: This is the first report to describe variable expressivity among individuals homozygous for p.(Gln48*). Previous literature has focused on heterozygous carriers with incomplete penetrance, and homozygous variability remains scarcely documented. CONCLUSIONS: Our findings expand the clinical and molecular spectrum of DRD and challenge the assumption that autosomal recessive GCH1 variants invariably cause a severe phenotype. This report underscores the importance of family-based genetic studies, detailed pedigrees, and careful clinical surveillance of asymptomatic carriers. A low threshold for levodopa trials is warranted, even when inheritance patterns or symptom severity deviate from classical expectations. These insights are critical to improving early recognition and timely treatment.
2026-01-24 | Phenotypic and genotypic heterogeneity in a series of cases associated with dopa-responsive dystonia.
Dopa-responsive dystonia (DRD) includes a group of neurological disorders that manifest with lower limb dystonia and an excellent response to levodopa. Parkinsonism is commonly associated with DRD, and many cases of GCH1 gene mutations without dystonia but with evidence of nigrostriatal pathway degeneration, indistinguishable to idiopathic Parkinson's disease (PD), have been recently described. This phenotypic variability has been observed even among members of the same family. Clinical and genetic description of 14 patients from 4 different families with DRD associated mutations. The results showed GCH1 mutations in three of the four families, while one family had a mutation in the SPR gene. Within patients with GCH1 mutations, two showed DRD symptoms, five had PD phenotype, and four were asymptomatic. The only patient with SPR mutation clinically displayed symptoms of dystonia and parkinsonism. DaTscan® revealed degeneration of the nigroestriatal pathway in two PD patients. Furthermore, phenotypic variability of the same mutation was observed in two families. DRD associated mutations have a heterogeneous clinical expression GCH1 gene mutations can be manifested with PD phenotype along with the degeneration of the nigroestiatal pathway. Therefore, GCH1 gene testing might be useful in cases of PD suggestive of genetic origin or with family history of dystonia.
2025-12-02 | L-DOPA in diurnal fluctuating dystonia: two different clinical presentations, one treatment.
Dopa-responsive dystonia (DRD) is a rare disorder in children and is notable for the fact that it can be effectively treated. The diagnosis of DRD assumes significant importance when there is a notable improvement in the patient's psychomotor and neurological development as a result of early intervention. The present case report aims to share two distinct clinical presentations, both firstly misdiagnosed as cerebral palsy and both had diurnal fluctuating of dystonia. In clinical presentations such as diurnal fluctuation suggestive of DRD, we aimed to emphasize that instead of waiting up to two years for genetic test results, evaluating the response to low-dose L-DOPA may support the patient's daily and vital functions during this period. Moving from treatment to diagnosis may still be a valid approach.
small molecules
2026-05-31 | Segawa Syndrome (Dopa-Responsive Dystonia): Current Concepts in Pathogenesis, Clinical Spectrum, Diagnosis, and Contemporary Management
Segawa syndrome, also known as dopa-responsive dystonia (DRD), is a rare inherited neurometabolic movement disorder characterized by childhood-onset dystonia, gait abnormalities, marked diurnal fluctuation, and dramatic responsiveness to low-dose levodopa therapy. [1,2] Since its original description by Segawa and colleagues in 1976, substantial advances have occurred in the understanding of the molecular genetics, neurotransmitter biochemistry, clinical heterogeneity, and therapeutic responsiveness of this disorder. [1,3] Classical Segawa syndrome is most commonly associated with autosomal dominant mutations involving the guanosine triphosphate cyclohydrolase I (GCH1) gene, resulting in impaired tetrahydrobiopterin (BH4) synthesis and subsequent dopamine deficiency within the nigrostriatal pathway. [3,4] Additional pathogenic variants involving TH, SPR, and related neurotransmitter biosynthetic pathways have expanded the phenotypic spectrum to include atypical and complex forms associated with parkinsonism, developmental delay, autonomic dysfunction, psychiatric manifestations, and cognitive impairment. [5,11] The disorder frequently presents diagnostic challenges because of significant phenotypic overlap with cerebral palsy, hereditary spastic paraplegia, juvenile Parkinson disease, idiopathic dystonia, and neurodegenerative disorders. [6,10,21] Delayed diagnosis remains common despite the existence of highly effective treatment, resulting in avoidable disability, skeletal deformities, psychosocial impairment, and reduced quality of life. [18,21] The hallmark clinical feature remains a dramatic and sustained response to levodopa therapy, which distinguishes DRD from most progressive neurodegenerative movement disorders. [8] Recent advances in molecular diagnostics, next-generation sequencing, cerebrospinal fluid neurotransmitter analysis, and functional neuroimaging have improved disease recognition and expanded understanding of genotype–phenotype correlations. [5,10,11] Nevertheless, contemporary controversies persist regarding diagnostic classification, atypical phenotypes, long-term disease progression, neuropsychiatric involvement, and optimization of individualized therapeutic strategies. [17,22] This comprehensive descriptive review examines the epidemiology, molecular pathogenesis, neurochemical mechanisms, clinical presentation, diagnostic evaluation, differential diagnosis, treatment approaches, prognosis, contemporary controversies, limitations of current evidence, and future research directions related to Segawa syndrome.
2026-05-19 | A case of dopa-responsive dystonia with a novel GCH1 variant c.579 C > G (p.Ile193Met).
Dopa-responsive dystonia (DRD) is an underdiagnosed inherited movement disorder characterized by childhood-onset progressive dystonia, diurnal symptom luctuation, and exquisite responsiveness to low-dose levodopa. Misdiagnosis as epilepsy, cerebral palsy, or juvenile Parkinsonism is common due to overlapping phenotypes and non-specific auxiliary examinations. A 22-year-old Chinese female presented with an 18-year history of right-sided limb and perioral involuntary movements, slurred speech, and progressive hypertonia. She was misdiagnosed with epilepsy for over a decade with no response to antiepileptic therapy. Brain MRI, EEG, and routine laboratory tests were unremarkable. Whole-exome sequencing (WES) identiied a heterozygous guanosine triphosphate cyclohydrolase-1 (GCH1) variant c.579C>G (p.Ile193Met), classified as a variant of uncertain signiicance (VUS) per American College of Medical Genetics and Genomics (ACMG) guidelines. Low-dose levodopa/benserazide (Madopar 0.125 g tid) induced dramatic symptomatic improvement, with sustained remission at 6-month follow-up. This case expands the GCH1 mutational spectrum of DRD and highlights the critical role of levodopa trial in unexplained dystonia, even in the absence of diurnal luctuation. Early recognition and intervention are pivotal for favorable prognosis.
2026-04-12 | Genetic analysis reveals phenotypic variability in three Colombian families with dopa-responsive dystonia: novel genotype-phenotype correlations.
BACKGROUND: Dopa-responsive Dystonia (DRD) due to GTP cyclohydrolase 1 (GTPCH1) deficiency is a neurogenetic disorder caused by pathogenic GCH1 variants. Tetrahydrobiopterin (BH4) deficiency impairs dopamine synthesis in the basal ganglia, leading to childhood-onset dystonia with excellent response to levodopa. CASE PRESENTATION: We report eight patients from three unrelated families with GCH1 (NM_000161.3) variants: c.142 C > T; p.(Gln48*), c.241T > C; p.(Ser81Pro), and c.607G > A; p.(Gly203Arg). Two individuals homozygous for c.142 C > T showed phenotypic discordance. Mean age at onset was 7.3 years (range: 6–12), with an average diagnostic delay of 13.4 years. All symptomatic individuals responded well to low-dose levodopa. DISCUSSION: This is the first report to describe variable expressivity among individuals homozygous for p.(Gln48*). Previous literature has focused on heterozygous carriers with incomplete penetrance, and homozygous variability remains scarcely documented. CONCLUSIONS: Our findings expand the clinical and molecular spectrum of DRD and challenge the assumption that autosomal recessive GCH1 variants invariably cause a severe phenotype. This report underscores the importance of family-based genetic studies, detailed pedigrees, and careful clinical surveillance of asymptomatic carriers. A low threshold for levodopa trials is warranted, even when inheritance patterns or symptom severity deviate from classical expectations. These insights are critical to improving early recognition and timely treatment.
2026-01-24 | Phenotypic and genotypic heterogeneity in a series of cases associated with dopa-responsive dystonia.
Dopa-responsive dystonia (DRD) includes a group of neurological disorders that manifest with lower limb dystonia and an excellent response to levodopa. Parkinsonism is commonly associated with DRD, and many cases of GCH1 gene mutations without dystonia but with evidence of nigrostriatal pathway degeneration, indistinguishable to idiopathic Parkinson's disease (PD), have been recently described. This phenotypic variability has been observed even among members of the same family. Clinical and genetic description of 14 patients from 4 different families with DRD associated mutations. The results showed GCH1 mutations in three of the four families, while one family had a mutation in the SPR gene. Within patients with GCH1 mutations, two showed DRD symptoms, five had PD phenotype, and four were asymptomatic. The only patient with SPR mutation clinically displayed symptoms of dystonia and parkinsonism. DaTscan® revealed degeneration of the nigroestriatal pathway in two PD patients. Furthermore, phenotypic variability of the same mutation was observed in two families. DRD associated mutations have a heterogeneous clinical expression GCH1 gene mutations can be manifested with PD phenotype along with the degeneration of the nigroestiatal pathway. Therefore, GCH1 gene testing might be useful in cases of PD suggestive of genetic origin or with family history of dystonia.
2025-12-02 | L-DOPA in diurnal fluctuating dystonia: two different clinical presentations, one treatment.
Dopa-responsive dystonia (DRD) is a rare disorder in children and is notable for the fact that it can be effectively treated. The diagnosis of DRD assumes significant importance when there is a notable improvement in the patient's psychomotor and neurological development as a result of early intervention. The present case report aims to share two distinct clinical presentations, both firstly misdiagnosed as cerebral palsy and both had diurnal fluctuating of dystonia. In clinical presentations such as diurnal fluctuation suggestive of DRD, we aimed to emphasize that instead of waiting up to two years for genetic test results, evaluating the response to low-dose L-DOPA may support the patient's daily and vital functions during this period. Moving from treatment to diagnosis may still be a valid approach.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.